Skip to main content
Journal cover image

Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Publication ,  Journal Article
Heimberger, AB; Sampson, JH
Published in: Neuro Oncol
January 2011

With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

January 2011

Volume

13

Issue

1

Start / End Page

3 / 13

Location

England

Related Subject Headings

  • Standard of Care
  • Oncology & Carcinogenesis
  • Immunotherapy
  • Humans
  • Glioblastoma
  • Brain Neoplasms
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Heimberger, A. B., & Sampson, J. H. (2011). Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol, 13(1), 3–13. https://doi.org/10.1093/neuonc/noq169
Heimberger, Amy B., and John H. Sampson. “Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Neuro Oncol 13, no. 1 (January 2011): 3–13. https://doi.org/10.1093/neuonc/noq169.
Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol. 2011 Jan;13(1):3–13.
Heimberger, Amy B., and John H. Sampson. “Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Neuro Oncol, vol. 13, no. 1, Jan. 2011, pp. 3–13. Pubmed, doi:10.1093/neuonc/noq169.
Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol. 2011 Jan;13(1):3–13.
Journal cover image

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

January 2011

Volume

13

Issue

1

Start / End Page

3 / 13

Location

England

Related Subject Headings

  • Standard of Care
  • Oncology & Carcinogenesis
  • Immunotherapy
  • Humans
  • Glioblastoma
  • Brain Neoplasms
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences